CSL Behring’s Berinert Gets Approval

July 26, 2016

The FDA has approved an expanded use for CSL Behring’s Berinert to include all age groups for the treatment of hereditary angioedema attacks.

Berinert is the only hereditary angioedema drug approved for children under 12 years of age.

The C1 esterase inhibitor is intended to treat acute abdominal, facial, and laryngeal attacks of hereditary angioedema attacks, according to the company.

View today's stories